2616.HK
2616.HK
KYG2588M1006
CSTONE PHARMA-B
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±72.5% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).

Beta (Market Relation)
0.22x
Defensive
Volatility (5Y p.a.)
72.5% p.a.
5-Year Horizon
Max Drawdown (5Y)
-92.5%
5-Year Horizon
Sharpe Ratio
-0.22
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -33.8%
3 Years 81.2% -69.6% 0.47 +40.6%
5 Years 72.5% -92.5% -0.22 -12.8%
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 145.4 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (81.2%) is noticeably higher than the 5Y average (72.5%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (72.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -92.5% in the extended horizon.
ende